Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience.

Luisa Edman KesslerOscar P B WiklanderEva HambergJonas BerghTheodoros FoukakisAlexios Matikas

Published in: Acta oncologica (Stockholm, Sweden) (2020)

CDK4/6i administered in a real-world setting exhibits a similar toxicity profile but higher incidence of treatment discontinuation compared to randomized trials. Efficacy of CDK4/6i among patients pretreated with multiple therapy lines is markedly reduced.

Keyphrases

cell cycle
metastatic breast cancer
risk factors
bone marrow
signaling pathway